SAIPARENT · NSE
Sai Parenterals Limited
₹510.75
+0.10% (+₹0.5)
Prev. close
₹510.25
Volume
34,306
Delivery %
66.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Sai Parenterals Limited
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, oncology, and dermatology in various dosage forms, including injectables, solid orals, liquid orals, and topicals. The company was founded in 1988 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. D. B. Venkoji Prakash
Headquarters
Hyderabad
Employees
293
Website
saiparenterals.comExchange
View on NSE ↗Key stats
Market cap
₹2,278.54 Cr
P/E ratio (TTM)
116.2
EPS (TTM)
₹4.44
Shares float
1.60 Cr
EPS · quarter ended Jun 2026
₹1.79
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide. Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹96.80 Cr | ₹153.76 Cr | ₹494.96 Cr | ₹381.00 Cr | |
| EBITDA | ₹18.77 Cr | ₹33.10 Cr | ₹54.35 Cr | ₹47.22 Cr |
| ₹4.38 Cr | ₹8.42 Cr | ₹19.63 Cr | — | |
| Diluted EPS | ₹0.99 | ₹1.9 | ₹4.44 | ₹4.36 |
Total expenses (as filed), Employee benefit expense, Other expenses, Net income, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹133.96 Cr | ₹268.10 Cr | ₹723.58 Cr | ₹1,424.23 Cr | |
| ₹68.55 Cr | ₹118.79 Cr | ₹203.66 Cr | — | |
| Stockholders' equity | ₹31.49 Cr | ₹74.55 Cr | ₹111.49 Cr | ₹490.77 Cr |
Trade receivables, Cash & equivalents, CWIP, Others, Total debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-12.80 Cr | ₹-29.76 Cr | ₹33.15 Cr | ₹93.05 Cr | |
| Investing cash flow | ₹-19.03 Cr | ₹-46.32 Cr | ₹43.50 L | ₹-273.83 Cr |
| ₹23.98 Cr | ₹78.57 Cr | ₹-35.88 Cr | ₹595.65 Cr | |
| Capital expenditure | ₹-17.34 Cr | ₹-44.10 Cr | ₹-50.00 L | ₹-66.95 Cr |
| End cash position | ₹1.91 Cr | ₹4.38 Cr | ₹2.09 Cr | ₹416.97 Cr |
Dividends paid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Mar 26–Jun 26(3Q) |
|---|---|
| Promoter | 51.16% |
| Public | 48.84% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sai Parenterals Limited | ₹2,249.16 Cr | ₹510.25 | 114.1 | 20.17 | 17.6% | 1.83 | +221.9% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.